Abstract: This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

Abstract: This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

Abstract: An air circulation system is provided that is fittable to a protective helmet. The system includes an external manifold, a removable intake duct, and a removable exhaust duct. The manifold is mountable to an external surface of a protective shell of a helmet and defines an exhaust passage external of the shell having at least one orifice communicable with an interior crown region of the shell and an intake passage communicable with a bottom region of the shell near a wearer's mouth and nose. The removable intake duct is connected to a remote positive pressure source at one end and connected to the external intake passage on the other end. The removable exhaust duct is connected to a remote source of negative pressure at one end and connected to the external exhaust passage of the external manifold on the other end.

Abstract: An air circulation system is provided that is fittable to a protective helmet. The system includes an external manifold, a removable intake duct, and a removable exhaust duct. The manifold is mountable to an external surface of a protective shell of a helmet and defines an exhaust passage external of the shell having at least one orifice communicable with an interior crown region of the shell and an intake passage communicable with a bottom region of the shell near a wearer's mouth and nose. The removable intake duct is connected to a remote positive pressure source at one end and connected to the external intake passage on the other end. The removable exhaust duct is connected to a remote source of negative pressure at one end and connected to the external exhaust passage of the external manifold on the other end.

Abstract: This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

Abstract: This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

Abstract: This invention provides compounds of formula I 1

Abstract: This invention provides compounds of formula I 1

Abstract: A method is described for forming a crystalline Echinocandin nucleus salt from its mixed broth and/or partially purified process streams by the steps of nanofiltration to form a concentrate, addition of an aldehyde derivatizing agent which interacts with an aldehyde impurity, addition of an acid/metal salt to form a solubilized echinocandin nucleus salt having the desired anion, and subsequent cooling of the mixture to crystallize the salt.

Abstract: A method is described for forming a crystalline Echinocandin nucleus salt from its mixed broth and/or partially purified process streams by the steps of nano-filtration to form a concentrate, addition of an aldehyde derivatizing agent which interacts with an aldehyde impurity, addition of an acid/metal salt to form a solubilized echinocandin nucleus salt having the desired anion, and subsequent cooling of the mixture to crystallize the salt.

Abstract: This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.